Latest Period
Q4 2025
- Info
- Insider Trading
- Financials
- Holders
Security Snapshot
Keros Therapeutics, Inc. - Common Stock (KROS) Institutional Ownership
CUSIP: 492327101
13F Institutional Holders and Ownership History from Q2 2020 to Q1 2026
Institutions Reporting
161
Shares (Excl. Options)
20,068,368
Price
$20.36
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock
- Symbol
- KROS on Nasdaq
- Shares outstanding
- 19,711,307
- Price per share
- $11.04
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 20,068,368
- Total reported value
- $408,413,646
- % of total 13F portfolios
- 0%
- Share change
- -15,029,057
- Value change
- -$274,881,622
- Number of holders
- 161
- Price from insider filings
- $11.04
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- KROS - Keros Therapeutics, Inc. - Common Stock is tracked under CUSIP 492327101.
- 161 institutions reported positions in Q4 2025.
- 7 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 161 to 13 between Q4 2025 and Q1 2026.
- Reported value moved from $408,413,646 to $765,951.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 161 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 492327101?
CUSIP 492327101 identifies KROS - Keros Therapeutics, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 492327101:
Significant Owners of Keros Therapeutics, Inc. - Common Stock (KROS) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 10% | $21,971,928 | 1,990,842 | BlackRock, Inc. | 31 Mar 2026 | |||
| ALKEON CAPITAL MANAGEMENT LLC | 2.7% | $15,645,210 | 1,101,000 | Alkeon Capital Management LLC | 31 Dec 2024 | |||
| Madison Avenue Partners, LP | 2.7% | -62% | $16,062,286 | -$34,918,552 | 823,707 | -68% | Madison Avenue International LP | 31 Dec 2025 |
| D. E. SHAW & CO, L.P. | 3.9% | -24% | $14,745,042 | -$15,400,944 | 756,156 | -51% | D. E. Shaw & Co., L.P. | 31 Dec 2025 |
| FMR LLC | 1.7% | $10,010,547 | 704,472 | FMR LLC | 31 Jan 2025 | |||
| JPMORGAN CHASE & CO | 0.2% | -102% | $1,617,141 | -$35,146,204 | 113,803 | -96% | JPMORGAN CHASE & CO. | 30 Apr 2025 |
| ExodusPoint Capital Management, LP | 0.04% | -104% | $260,520 | -$36,943,510 | 13,360 | -99% | ExodusPoint Capital Management, LP | 31 Dec 2025 |
As of 31 Dec 2025, 161 institutional investors reported holding 20,068,368 shares of Keros Therapeutics, Inc. - Common Stock (KROS). This represents 102% of the company’s total 19,711,307 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Keros Therapeutics, Inc. - Common Stock (KROS) together control 81% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 12% | 2,290,532 | -16% | 0% | $46,635,220 |
| VANGUARD GROUP INC | 7.7% | 1,525,355 | -44% | 0% | $31,056,228 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 6.8% | 1,334,516 | +416% | 0.02% | $27,170,746 |
| STATE STREET CORP | 5.5% | 1,075,993 | -17% | 0% | $21,907,217 |
| Madison Avenue Partners, LP | 4.2% | 823,707 | -70% | 0.72% | $16,770,675 |
| ORBIMED ADVISORS LLC | 4.1% | 804,212 | -21% | 0.35% | $16,373,756 |
| Qube Research & Technologies Ltd | 4% | 783,918 | +159% | 0.02% | $15,960,570 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 3.9% | 768,425 | +27% | 0.06% | $15,645,133 |
| D. E. Shaw & Co., Inc. | 3.8% | 755,473 | -43% | 0.01% | $15,381,430 |
| FEDERATED HERMES, INC. | 3.3% | 654,724 | +27% | 0.02% | $13,330,180 |
| GEODE CAPITAL MANAGEMENT, LLC | 3.2% | 635,208 | -24% | 0% | $12,935,496 |
| RENAISSANCE TECHNOLOGIES LLC | 3% | 591,686 | +282% | 0.02% | $12,046,727 |
| GOLDMAN SACHS GROUP INC | 3% | 590,517 | -55% | 0% | $12,022,926 |
| CITADEL ADVISORS LLC | 2.4% | 472,520 | +168% | 0.01% | $9,620,507 |
| Nantahala Capital Management, LLC | 1.8% | 360,419 | -71% | 0.44% | $7,338,131 |
| Connor, Clark & Lunn Investment Management Ltd. | 1.6% | 321,346 | -4.1% | 0.02% | $6,542,605 |
| TWO SIGMA INVESTMENTS, LP | 1.6% | 318,439 | +286% | 0.01% | $6,483,418 |
| HRT FINANCIAL LP | 1.3% | 260,891 | +510% | 0.02% | $5,311,000 |
| Weiss Asset Management LP | 1.3% | 254,063 | 0.08% | $5,172,723 | |
| NORTHERN TRUST CORP | 1.3% | 250,571 | -25% | 0% | $5,101,626 |
| MORGAN STANLEY | 1.2% | 230,492 | -42% | 0% | $4,692,833 |
| MILLENNIUM MANAGEMENT LLC | 1.1% | 220,209 | +313% | 0% | $4,483,455 |
| DEUTSCHE BANK AG\ | 0.99% | 195,281 | +740% | 0% | $3,975,921 |
| ALGERT GLOBAL LLC | 0.98% | 193,607 | +305% | 0.06% | $3,942,000 |
| Man Group plc | 0.96% | 190,207 | -1.4% | 0.01% | $3,872,615 |
Institutional Holders of Keros Therapeutics, Inc. - Common Stock (KROS) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 69,361 | $765,951 | -$1,084,783 | $11.04 | 13 |
| 2025 Q4 | 20,068,368 | $408,413,646 | -$274,881,622 | $20.36 | 161 |
| 2025 Q3 | 35,272,212 | $558,014,186 | -$7,638,925 | $15.82 | 151 |
| 2025 Q2 | 35,922,272 | $479,567,957 | +$53,894,426 | $13.35 | 134 |
| 2025 Q1 | 32,796,190 | $334,208,916 | -$101,548,195 | $10.19 | 154 |
| 2024 Q4 | 36,741,918 | $581,640,265 | -$99,583,348 | $15.83 | 159 |
| 2024 Q3 | 34,948,467 | $2,029,993,469 | +$197,656,348 | $58.07 | 162 |
| 2024 Q2 | 31,483,081 | $1,437,735,495 | -$1,704,535 | $45.70 | 150 |
| 2024 Q1 | 31,378,208 | $2,077,197,760 | +$376,189,592 | $66.20 | 144 |
| 2023 Q4 | 25,748,679 | $1,023,986,857 | +$107,389,201 | $39.76 | 119 |
| 2023 Q3 | 22,915,590 | $730,562,303 | +$10,983,703 | $31.88 | 106 |
| 2023 Q2 | 22,423,232 | $900,980,099 | +$13,493,306 | $40.18 | 121 |
| 2023 Q1 | 22,003,238 | $936,983,921 | +$94,494,039 | $42.70 | 128 |
| 2022 Q4 | 19,814,952 | $951,517,038 | +$88,887,412 | $48.02 | 122 |
| 2022 Q3 | 18,166,429 | $683,394,048 | +$33,259,877 | $37.62 | 107 |
| 2022 Q2 | 17,360,328 | $479,673,115 | +$10,253,619 | $27.63 | 101 |
| 2022 Q1 | 16,425,972 | $892,979,574 | +$13,785,386 | $54.38 | 101 |
| 2021 Q4 | 16,155,340 | $944,400,680 | +$68,408,989 | $58.51 | 96 |
| 2021 Q3 | 13,732,777 | $543,300,250 | -$15,835,150 | $39.56 | 86 |
| 2021 Q2 | 14,120,390 | $599,680,759 | -$43,588,395 | $42.47 | 79 |
| 2021 Q1 | 14,412,080 | $887,014,019 | -$122,639,102 | $61.55 | 83 |
| 2020 Q4 | 16,029,747 | $1,129,296,879 | +$301,336,670 | $70.54 | 81 |
| 2020 Q3 | 11,780,724 | $454,579,430 | +$33,779,230 | $38.57 | 49 |
| 2020 Q2 | 10,926,163 | $409,790,602 | +$409,790,602 | $37.51 | 51 |